Objectives: To investigate the microorganisms in expressed prostatic secretions (EPS) of both chronic prostatitis patients and normal young male adults and to determine which microorganisms are associated with the degree of intraprostatic inflammation. Methods: Specific polymerase chain reaction (PCR) technology was performed to confirm Neisseria gonorrhoeae, Mycobacterium tuberculosis, Mycoplasma and Chlamydia trachomatis as well as human papilloma virus (HPV), herpes simplex virus type 2 (HSV-2) and cytomegalovirus (CMV). Universal primer PCR technology was carried out to detect 16S bacteria rDNA, followed by cloning and sequencing of the entire 16S rDNA product. Results: The total number of bacteria and/or viruses detected by PCR assays was significantly associated with disease severity (p < 0.001). The white blood cell count and lecithin level was significantly correlated with the number of detected bacteria and/or viruses (p = 0.001 and p = 0.046, respectively). 17 bacterial isolates were identified from 14 EPS samples by 16S rDNA sequencing. Conclusions: Various microorganisms including Ureaplasma urealyticum, C. trachomatis, CMV, HPV and HSV-2 were identified in the EPS from patients with type III prostatitis. HPV infection may be associated with the degree of intraprostatic inflammation.

Keywords:
Chronic prostatitis, Microorganism, Etiology, Sequencing, Expressed prostatic secretions, Intraprostatic inflammation
1.
Xia SJ, Cui D, Jiang Q: An overview of prostate diseases and their characteristics specific to Asian men. Asian J Androl 2012;14:458-464.
2.
Lovejoy B: Diagnosis and management of chronic prostatitis by primary care providers. J Am Acad Nurse Pract 2001;13:317-324.
3.
Krieger JN, Riley DE: Prostatitis: what is the role of infection? Int J Antimicrob Agents 2002;19:475-479.
4.
Cai T, Mazzoli S, Meacci F, et al: Epidemiological features and resistance pattern in uropathogens isolated from chronic bacterial prostatitis. J Microbiol 2011;49:448-454.
5.
Zhou Z, Hong L, Shen X, et al: Detection of nanobacteria infection in type III prostatitis. Urology 2008;71:1091-1095.
6.
Skerk V, Krhen I, Schonwald S, et al: The role of unusual pathogens in prostatitis syndrome. Int J Antimicrob Agents 2004;24(suppl 1): S53-S56.
7.
Schaeffer AJ, Knauss JS, Landis JR, et al; Chronic Prostatitis Collaborative Research Network Study Group: Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis: the National Institutes of Health Chronic Prostatitis Cohort Study. J Urol 2002;168:1048-1053.
8.
Zdrodowska-Stefanow B, Kłosowska WM, Ostaszewska-Puchalska I, Bułhak-Kozioł V, Kotowicz B: Ureaplasma urealyticum and Mycoplasma hominis infection in women with urogenital diseases. Adv Med Sci 2008;51:250-253.
9.
Shoskes DA, Shahed AR: Detection of bacterial signal by 16S rRNA polymerase chain reaction in expressed prostatic secretions predicts response to antibiotic therapy in men with chronic pelvic pain syndrome. Tech Urol 2000;6:240-242.
10.
Toyokawa M, Kishimoto T, Cai Y, et al: Severe Chlamydophila psittaci pneumonia rapidly diagnosed by detection of antigen in sputum with an immunochromatography assay. J Infect Chemother 2004;10:245-249.
11.
Lane DJ: 16S/23S rRNA sequencing; in Stackebrandt E, Goodfellow M (eds): Nucleic Acid Techniques in Bacterial Systematics. Wiley, Chichester, 1991, pp 115-175.
12.
Lan T, Wang Y, Chen Y, et al: Influence of environmental factors on prevalence, symptoms, and pathologic process of chronic prostatitis/chronic pelvic pain syndrome in northwest China. Urology 2011;78:1142-1149.
13.
Lobel B, Rodriguez A: Chronic prostatitis: what we know, what we do not know, and what we should do! World J Urol 2003;21:57-63.
14.
Lee JC, Muller CH, Rothman I, et al: Prostate biopsy culture findings of men with chronic pelvic pain syndrome do not differ from those of healthy controls. J Urol 2003;169:584-588.
15.
Mandar R, Raukas E, Turk S, et al: Mycoplasmas in semen of chronic prostatitis patients. Scand J Urol Nephrol 2005;39:479-482.
16.
Mazzoli S, Cai T, Rupealta V, et al: Interleukin 8 and anti-chlamydia trachomatis mucosal IgA as urogenital immunologic markers in patients with C. trachomatis prostatic infection. Eur Urol 2007;51:1385-1393.
17.
Leskinen MJ, Vainionp R, Syrjnen S, et al: Herpes simplex virus, cytomegalovirus, and papillomavirus DNA are not found in patients with chronic pelvic pain syndrome undergoing radical prostatectomy for localized prostate cancer. Urology 2003;61:397-401.
18.
Guercini F, Pajoncini C, Bard R, et al: Echoguided drug infiltration in chronic prostatitis: results of a multi-centre study. Arch Ital Urol Androl 2005;77:87-92.
19.
Centers for Disease Control and Prevention, Workowski KA, Berman SM: Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006;55 (RR-11):38.
20.
Gu R, Zhou C, Ma Q: Correlation between EPS composition and elevated serum PSA in prostatitis patients (in Chinese). Zhonghua Nan Ke Xue 2004;10:423-425.
21.
Krieger JN, Ross SO, Limaye AP, Riley DE: Inconsistent localization of Gram-positive bacteria to prostate-specific specimens from patients with chronic prostatitis. Urology 2005;66:721-725.
22.
Budía A, Luis Palmero J, Broseta E, et al: Value of semen culture in the diagnosis of chronic bacterial prostatitis: a simplified method. Scand J Urol Nephrol 2006;40:326-331.
23.
Ateya A, Fayez A, Hani R, Zohdy W, Gabbar MA, Shamloul R: Evaluation of prostatic massage in treatment of chronic prostatitis. Urology 2006;67:674-678.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.